https://stock.noler.com/us/stock/shangpharma-corp https://stock.noler.com/us/stock/shangpharma-corp/accounts-payable https://stock.noler.com/us/stock/shangpharma-corp/accounts-receivable https://stock.noler.com/us/stock/shangpharma-corp/accrued-income-taxes-current https://stock.noler.com/us/stock/shangpharma-corp/additional-paid-in-capital https://stock.noler.com/us/stock/shangpharma-corp/amortization https://stock.noler.com/us/stock/shangpharma-corp/aoci https://stock.noler.com/us/stock/shangpharma-corp/assets-noncurrent https://stock.noler.com/us/stock/shangpharma-corp/basic-shares https://stock.noler.com/us/stock/shangpharma-corp/buybacks-share-repurchases https://stock.noler.com/us/stock/shangpharma-corp/buybacks-treasury-stock-cost https://stock.noler.com/us/stock/shangpharma-corp/capital-expenditures https://stock.noler.com/us/stock/shangpharma-corp/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/shangpharma-corp/cash-and-equivalents https://stock.noler.com/us/stock/shangpharma-corp/cash-flow-breakdown https://stock.noler.com/us/stock/shangpharma-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/shangpharma-corp/common-stock-value https://stock.noler.com/us/stock/shangpharma-corp/comprehensive-income https://stock.noler.com/us/stock/shangpharma-corp/cost-of-revenue https://stock.noler.com/us/stock/shangpharma-corp/cost-of-revenue-2 https://stock.noler.com/us/stock/shangpharma-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/shangpharma-corp/current-assets https://stock.noler.com/us/stock/shangpharma-corp/current-liabilities https://stock.noler.com/us/stock/shangpharma-corp/customer-advances-current https://stock.noler.com/us/stock/shangpharma-corp/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/shangpharma-corp/deferred-tax-assets-net-current https://stock.noler.com/us/stock/shangpharma-corp/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/shangpharma-corp/depreciation-and-amortization https://stock.noler.com/us/stock/shangpharma-corp/derivative-assets-noncurrent https://stock.noler.com/us/stock/shangpharma-corp/diluted-shares https://stock.noler.com/us/stock/shangpharma-corp/due-from-related-parties-current https://stock.noler.com/us/stock/shangpharma-corp/due-from-related-parties-noncurrent https://stock.noler.com/us/stock/shangpharma-corp/due-to-related-parties-current https://stock.noler.com/us/stock/shangpharma-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/shangpharma-corp/eps https://stock.noler.com/us/stock/shangpharma-corp/eps-basic https://stock.noler.com/us/stock/shangpharma-corp/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/shangpharma-corp/financing-cash-flow https://stock.noler.com/us/stock/shangpharma-corp/gain-loss-on-investments https://stock.noler.com/us/stock/shangpharma-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/shangpharma-corp/general-and-administrative-expense https://stock.noler.com/us/stock/shangpharma-corp/gross-profit https://stock.noler.com/us/stock/shangpharma-corp/impairment-of-investments https://stock.noler.com/us/stock/shangpharma-corp/income-tax https://stock.noler.com/us/stock/shangpharma-corp/income-taxes-paid https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-customer-advances https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-other-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/shangpharma-corp/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/shangpharma-corp/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/shangpharma-corp/interest-expense https://stock.noler.com/us/stock/shangpharma-corp/interest-paid https://stock.noler.com/us/stock/shangpharma-corp/inventory https://stock.noler.com/us/stock/shangpharma-corp/inventory-write-down https://stock.noler.com/us/stock/shangpharma-corp/investing-cash-flow https://stock.noler.com/us/stock/shangpharma-corp/investment-income-interest https://stock.noler.com/us/stock/shangpharma-corp/liabilities-noncurrent https://stock.noler.com/us/stock/shangpharma-corp/net-change-in-cash https://stock.noler.com/us/stock/shangpharma-corp/net-income https://stock.noler.com/us/stock/shangpharma-corp/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/shangpharma-corp/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/shangpharma-corp/operating-cash-flow https://stock.noler.com/us/stock/shangpharma-corp/operating-expenses https://stock.noler.com/us/stock/shangpharma-corp/operating-income https://stock.noler.com/us/stock/shangpharma-corp/other-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/shangpharma-corp/other-cost-and-expense-operating https://stock.noler.com/us/stock/shangpharma-corp/other-noncurrent-assets https://stock.noler.com/us/stock/shangpharma-corp/other-nonoperating-expense https://stock.noler.com/us/stock/shangpharma-corp/other-nonoperating-income https://stock.noler.com/us/stock/shangpharma-corp/other-operating-income https://stock.noler.com/us/stock/shangpharma-corp/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/shangpharma-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/shangpharma-corp/payments-for-proceeds-from-derivative-instrument-investing-activities https://stock.noler.com/us/stock/shangpharma-corp/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/shangpharma-corp/payments-to-acquire-investments https://stock.noler.com/us/stock/shangpharma-corp/preferred-shares-facts https://stock.noler.com/us/stock/shangpharma-corp/preferred-stock-dividends-and-other-adjustments https://stock.noler.com/us/stock/shangpharma-corp/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/shangpharma-corp/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/shangpharma-corp/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/shangpharma-corp/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/shangpharma-corp/proceeds-from-short-term-debt https://stock.noler.com/us/stock/shangpharma-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/shangpharma-corp/property-plant-equipment https://stock.noler.com/us/stock/shangpharma-corp/provision-for-doubtful-accounts https://stock.noler.com/us/stock/shangpharma-corp/related-party-costs https://stock.noler.com/us/stock/shangpharma-corp/repayments-of-short-term-debt https://stock.noler.com/us/stock/shangpharma-corp/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/shangpharma-corp/retained-earnings-appropriated https://stock.noler.com/us/stock/shangpharma-corp/retained-earnings-unappropriated https://stock.noler.com/us/stock/shangpharma-corp/revenue https://stock.noler.com/us/stock/shangpharma-corp/selling-and-marketing-expense https://stock.noler.com/us/stock/shangpharma-corp/shareholders-equity https://stock.noler.com/us/stock/shangpharma-corp/shares-authorized https://stock.noler.com/us/stock/shangpharma-corp/shares-issued https://stock.noler.com/us/stock/shangpharma-corp/short-term-bank-loans-and-notes-payable https://stock.noler.com/us/stock/shangpharma-corp/stock-based-compensation https://stock.noler.com/us/stock/shangpharma-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/shangpharma-corp/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/shangpharma-corp/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/shangpharma-corp/total-assets https://stock.noler.com/us/stock/shangpharma-corp/total-liabilities https://stock.noler.com/us/stock/shangpharma-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/shangpharma-corp/treasury-stock-shares https://stock.noler.com/us/stock/shangpharma-corp/treasury-stock-value https://stock.noler.com/us/stock/shangpharma-corp/unrealized-gain-loss-on-derivatives